Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Total Debt (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Total Debt data on record, last reported at $570.2 million in Q3 2025.

  • For Q3 2025, Total Debt fell 4.12% year-over-year to $570.2 million; the TTM value through Sep 2025 reached $570.2 million, down 4.12%, while the annual FY2024 figure was $579.7 million, 43.12% up from the prior year.
  • Total Debt reached $570.2 million in Q3 2025 per COLL's latest filing, down from $585.2 million in the prior quarter.
  • Across five years, Total Debt topped out at $628.4 million in Q1 2022 and bottomed at $110.0 million in Q4 2021.
  • Average Total Debt over 5 years is $441.1 million, with a median of $537.1 million recorded in 2023.
  • Peak YoY movement for Total Debt: surged 409.07% in 2022, then crashed 35.9% in 2024.
  • A 5-year view of Total Debt shows it stood at $110.0 million in 2021, then soared by 409.07% to $560.1 million in 2022, then decreased by 27.68% to $405.0 million in 2023, then soared by 43.12% to $579.7 million in 2024, then dropped by 1.64% to $570.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $570.2 million in Q3 2025, $585.2 million in Q2 2025, and $600.3 million in Q1 2025.